Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.49 |
| ▸ | PDE4A | P27815 | 7/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11270394 | 0.94 | ADORA2B (0.53) | ALDH1A1KDM4EHPGDADORA2APDE4A | |
| SCHEMBL1866522 | 0.91 | PDE4A (0.49) | ALDH1A1HPGDADORA2APDE4APDE4B | |
| SCHEMBL26248657 | 0.84 | ALDH1A1 (0.47) | ALDH1A1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6673901 | 0.76 | ADORA2A (0.52) | ALDH1A1HPGDADORA2APDE4APDE4B | |
| SCHEMBL26248690 | 0.76 | ADORA2A (0.54) | ALDH1A1KDM4EHPGDADORA2APDE4A | |
| SCHEMBL2115743 | 0.75 | ALDH1A1 (0.52) | ALDH1A1KDM4EADORA2APDE4APDE4B | |
| SCHEMBL5616439 | 0.74 | ADORA2B (0.49) | ALDH1A1KDM4EHPGDADORA2APDE4A | |
| SCHEMBL7684917 | 0.73 | ALDH1A1 (0.42) | ALDH1A1ADORA2BADORA3 | |
| SCHEMBL6272735 | 0.72 | PDE4A (0.59) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10528220 | 0.72 | ADORA2B (0.43) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002085904-A1 | SNYTHESIS AND METHODS OF USE OF PURINE ANALOGUES AND DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | NEO THERAPEUTICS, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | SLC29A1, ATIC, PNP | ALDH1A1 834/4885KDM4E 2916/4885HPGD 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.